O linfoma de Hodgkin clássico (CHL) é um linfoma de células B caracterizado histologicamente pela presença de grandes células de Hodgkin mononucleares e células multinucleadas de Reed-Sternberg (HRS).
Introdução
O que você precisa saber de cara
O linfoma de Hodgkin clássico (CHL) é um linfoma de células B caracterizado histologicamente pela presença de grandes células de Hodgkin mononucleares e células multinucleadas de Reed-Sternberg (HRS).
Tem tratamento?
Escala de raridade
<1/50kMuito rara
1/20kRara
1/10kPouco freq.
1/5kIncomum
1/2k
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 14 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 36 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição. Padrão de herança: Unknown.
Involved in pinching off the separated nuclei at the cleavage furrow and in cytokinesis (PubMed:20107318). Required for mitotic integrity and maintenance of chromosomal stability. Protects cells against mitotic errors, centrosomal amplification, micronucleus formation and aneuploidy. Plays a key role of midbody function involving abscission of the daughter cells during cytokinesis and appropriate chromosomal and nuclear segregation into the daughter cells (PubMed:22988245, PubMed:23713010)
CytoplasmMidbody
Lymphoma, Hodgkin, classic
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed-Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.
Medicamentos e terapias
Mecanismo: Programmed cell death protein 1 inhibitor
Mecanismo: Granulocyte colony stimulating factor receptor agonist
Mecanismo: Glucocorticoid receptor agonist
Mecanismo: Tubulin inhibitor
Mecanismo: DNA topoisomerase II alpha inhibitor
Mecanismo: Tubulin inhibitor
Mecanismo: Tubulin inhibitor
Mecanismo: DNA polymerase (alpha/delta/epsilon) inhibitor
Mecanismo: Tubulin inhibitor
Variantes genéticas (ClinVar)
18 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 8 variantes classificadas pelo ClinVar.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Doença de Hodgkin
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
18 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
200 ensaios clínicos encontrados, 36 ativos.
Publicações mais relevantes
Mostrando amostra de 200 publicações de um total de 729
Classic hodgkin lymphoma associated with Epstein-Barr virus reactivation during vedolizumab therapy for ulcerative colitis.
Epstein-Barr virus (EBV)-associated lymphoproliferative disorders have been reported in patients receiving immunosuppressive therapy for inflammatory bowel disease; however, the onset of classic Hodgkin lymphoma (cHL) during vedolizumab therapy is extremely rare. A 73 year-old woman with ulcerative colitis (UC) was steroid-dependent, showing disease exacerbation when prednisolone was tapered or discontinued. Azathioprine was administered eight years prior but was discontinued after a short period due to liver dysfunction. Vedolizumab was initiated 31 months before presentation. Despite initial improvements in UC with vedolizumab, hematochezia subsequently persisted. Other biologics or immunomodulators that could cause systemic immunosuppression were avoided because she was receiving treatment for breast cancer. Colonoscopy showed erosions in the transverse colon and an ulcerative lesion in the sigmoid colon. A biopsy revealed high-grade dysplasia in the transverse colon and inflammatory granulation tissue without malignancy in the sigmoid lesion; therefore, surgery was indicated. Laparoscopic total proctocolectomy was performed, and the surgical specimen contained Reed-Sternberg cells positive for CD20, CD30, PD-L1, and EBV-encoded RNA, establishing EBV-associated cHL. Although the development of cHL is likely multifactorial, clinicians should be aware that EBV-associated intestinal cHL may develop in patients with UC receiving vedolizumab when tumor-like ulcers or mural thickening are encountered.
A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.
The Phase 1/2 Intergroup study E4412 (NCT01896999; ClinicalTrials.gov) investigated checkpoint blockade with nivolumab (Nivo) and ipilimumab (Ipi) in relapsed/refractory (R/R) classic Hodgkin lymphoma (HL) while concurrently targeting CD30+ Hodgkin Reed Sternberg cells with the antibody-drug conjugate brentuximab vedotin (BV). 147 patients ≥12 years were randomized between BV/Nivo and BV/Ipi/Nivo; 132 patients are included in primary efficacy analysis. The primary endpoint, complete response (CR) rate, was 64.7% (52.2, 75.9) for BV/Nivo and 70.3% (57.6, 81.1) for BV/Ipi/Nivo (one-sided p=0.29). The median survival follow-up is 38.0 months (interquartile range 32.6-48.1). Progression-free survival (PFS) did not significantly differ between the two arms (HR=0.78, CI 0.39-1.57, one-sided p=0.24). Treatment-related grade 3+ toxicities in the adult cohort, excluding rash, was similar between both arms (38.5% BV/Nivo and 39.3% BV/Ipi/Nivo); there was higher frequency of grade 3 rash with BV/Ipi/Nivo (24.6%) compared to BV/Nivo (9.2%). We compared PFS by stem cell transplantation (SCT) status in a planned post-hoc comparison; 58 patients received SCT; 36-month PFS (from SCT) was greater than 90% for both arms. Sixty-six patients were alive and progression free after the first scan (disease evaluation) and did not undergo SCT. The 36-month PFS (from first scan) was 73.0% (54.5, 85.0) for BV/Ipi/Nivo compared to 45.8% (26.3, 63.4) for BV/Nivo (HR=0.45, CI 0.19-1.08, one-sided p=0.03). The study did not meet its primary endpoint of superior CR rate for the triplet, but it supports the use of checkpoint-ADC induction prior to auto SCT, and there is an intriguing signal of disease control for patients wishing to defer or avoid SCT for the triplet of BV/Ipi/Nivo.
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.
We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.
Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq.
Classical Hodgkin lymphoma (CHL) is characterized by a complex tumor microenvironment (TME) that supports disease progression. Although immune cell recruitment by Hodgkin and Reed-Sternberg (HRS) cells is well documented, the role of nonmalignant B cells in relapse remains unclear. Using single-cell RNA sequencing (scRNA-seq) on paired diagnostic and relapsed CHL samples, we identified distinct shifts in B-cell populations, particularly an enrichment of naïve B cells and a reduction of memory B cells in early-relapse CHL compared to late-relapse and newly diagnosed CHL. The enrichment of naïve B cells in early relapse biopsies was confirmed in independent validation cohorts using scRNA-seq and immunohistochemistry. Notably, naïve B cells in early-relapse samples exhibited high expression of LGALS9, an immunosuppressive gene encoding galectin-9, which binds to HAVCR2 (T-cell immunoglobulin and mucin domain-containing protein 3 [TIM-3]) on regulatory T cells (Tregs). Cell-cell interaction analysis revealed the importance of interactions between LGALS9+ naïve B cells and HAVCR2+ Tregs in the early-relapse setting. Spatial analysis by imaging mass cytometry confirmed close proximity of galectin-9-positive naïve B cells with TIM-3+ CD4+ T cells and HRS cells, pointing to their role in shaping an immunosuppressive niche. Our findings highlight a previously unrecognized population of galectin-9-positive naïve B cells with immunoregulatory potential in early-relapse CHL and provide new insights into the spatial and transcriptional architecture of the relapsed TME in CHL.
Clinicopathologic patterns and treatment outcomes of pediatric classic hodgkin lymphoma in Ethiopian newly opened cancer treatment centers.
Publicações recentes
Gene expression profile of adult T-cell leukemia/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia/lymphoma.
Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial.
SSTR2 expression in EBV-positive and EBV-negative lymphomas.
Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.
Successful Treatment of Isolated Bone Marrow Classic Hodgkin Lymphoma in a Patient With Cartilage Hair Hypoplasia.
📚 EuropePMC431 artigos no totalmostrando 199
Clinicopathologic patterns and treatment outcomes of pediatric classic hodgkin lymphoma in Ethiopian newly opened cancer treatment centers.
BMC pediatricsA case of secondary papuloerythroderma of Ofuji associated with classic Hodgkin lymphoma.
European journal of dermatology : EJDCD47 Expression in Classic Hodgkin Lymphoma and Its Association With Tumor Microenvironment.
Journal of immunology researchComprehensive Assessment of CD19 Immunohistochemical Staining in Classic Hodgkin Lymphoma.
The American journal of surgical pathologyExome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursors.
Cancer geneticsBleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.
HaematologicaClassic hodgkin lymphoma associated with Epstein-Barr virus reactivation during vedolizumab therapy for ulcerative colitis.
Clinical journal of gastroenterologyAnti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysis.
HaematologicaPrognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort study.
British journal of haematologyClassic Hodgkin Lymphoma in the Older Adult: What's New?
Hematology/oncology clinics of North AmericaAn Unusual Case of Classic Hodgkin Lymphoma With Strong Expression of B-Cell Markers.
International journal of laboratory hematologyOptimizing the Role of Checkpoint Inhibitors in the Management of Hodgkin Lymphoma.
Journal of the National Comprehensive Cancer Network : JNCCNPrognostic Impact of CD57⁺ Natural Killer Cells and CD138⁺ Plasma Cells as Minor Components of the Tumor Microenvironment in Mixed Cellularity Classical Hodgkin Lymphoma.
Applied immunohistochemistry & molecular morphology : AIMMThe Modern Role of Radiation Therapy in Classic Hodgkin Lymphoma.
Hematology/oncology clinics of North AmericaFollicular lymphoma transformed to classic Hodgkin lymphoma.
BloodHodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCNCellular and Novel Immunotherapies for Classic Hodgkin Lymphoma.
Hematology/oncology clinics of North AmericaNew Developments in Hodgkin's Lymphoma: Outcomes and Disparities in Classic Hodgkin Lymphoma.
Hematology/oncology clinics of North AmericaA Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.
BloodSubsequent Neoplasm Risk After Modern Mediastinal Radiation Therapy for Pediatric Hodgkin Lymphoma: Insights From a Multi-Institutional Children's Oncology Group Trial.
International journal of radiation oncology, biology, physicsManagement of Classic Hodgkin Lymphoma in Pregnancy.
Hematology/oncology clinics of North AmericaVanishing Bile Duct Syndrome as a Rare Complication of Classic Hodgkin's Lymphoma: A Case Report and Literature Review.
CureusMultidimensional Characterization of Tumor-Immune Architecture Reveals Clinically Relevant Classic Hodgkin Lymphoma Subtypes.
Cancer discoveryThe Role of Stem Cell Transplantation in Hodgkin Lymphoma.
Hematology/oncology clinics of North AmericaPrognostic role of PET/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group.
British journal of haematologyCirculating Tumor DNA Assessment in Classic Hodgkin Lymphoma: Ready for Primetime?
Hematology/oncology clinics of North America[Combination lymphomas, grey zone lymphomas and future challenges].
Pathologie (Heidelberg, Germany)Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyProcalcitonin as a Potential Prognostic Marker in Advanced Hodgkin Lymphoma: A Case-Based Perspective.
CureusSelection of a Salvage Regimen for Relapsed or Refractory Classic Hodgkin Lymphoma in the Era of Novel Therapies.
Hematology/oncology clinics of North AmericaInternational Cost-Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced-Stage Classic Hodgkin's Lymphoma.
Hematological oncologyPIM kinase inhibition attenuates pro-tumoral and immunosuppressive functions of macrophages in classic Hodgkin lymphoma.
Cell death & diseaseEpidemiological evidence for the role of puberty and immune senescence in Hodgkin lymphoma aetiology from 1992 Danish cases.
International journal of cancerThe importance of assessing the fitness of older patients with newly diagnosed diffuse large B-cell lymphoma and classic Hodgkin lymphoma.
British journal of haematologyBeyond PD-1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next-Generation Immune Strategies.
European journal of haematologyIpilimumab with and without nivolumab in patients with classic Hodgkin lymphoma with progression after PD-1 blockade.
Blood neoplasiaSurgical Resection of a Refractory Lung Abscess Secondary to Classic Hodgkin Lymphoma.
Annals of thoracic surgery short reportsHistological subtypes of rheumatoid arthritis-associated lymphoproliferative disorders: Serological and Epstein-Barr virus findings.
Modern rheumatologyClassic Hodgkin lymphoma in a patient with Behçet's disease: a case report and review of the literature.
Clinical rheumatologyRedefining the Spectrum of Epstein-Barr Virus-Positive (EBV+) Diffuse Large B-cell Lymphoma and EBV+ Classic Hodgkin Lymphoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMantle cell lymphoma transformation to CD19-negative classic Hodgkin lymphoma as a novel mechanism of escape from CD19 chimeric antigen receptor T cell therapy.
Journal of hematopathologySuccessful Neutrophil Engraftment with Continued Ruxolitinib in Cord Blood Transplantation.
Blood cell therapyEpstein-Barr virus-associated lymphomas: biology, molecular genomics and precision oncology.
Frontiers in oncologyCase Report: Pitfalls in bone marrow evaluation: importance of adequate bone marrow sampling.
Frontiers in oncologyA Rare Case of Bullous Pemphigoid Triggered by Overlapping Immune Dysregulation From HIV and Hodgkin Lymphoma: A Case Report.
Cureus"I Missed My Other Oncologist": Established Relationships as Barriers and Facilitators to Accessing CAR-T and Autologous Transplantation.
Cancer medicineAwake thoracoscopic mediastinal biopsy in a teenager: a case report.
Journal of pediatric surgery case reportsEarly-stage Hodgkin lymphoma in Cape Town, South Africa: prognostic risk factors at diagnosis and treatment outcomes.
BMC cancerEpstein-Barr virus-transformed B-cells from a hypoxia model of the germinal center requires external unsaturated fatty acids.
PLoS pathogensClassic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma.
BloodFeasibility and safety of anti-PD1 first-line treatment of classic Hodgkin lymphoma: do we see the full picture?
BloodAdvanced Stage IVb Classical Hodgkin's Lymphoma in a 9/11 First Responder: The Persistent Health Risks and Impact of Environmental Exposures.
CureusEfficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study.
Advances in hematologyBLNK as an important prognostic indicator for survival in pediatric classic hodgkin lymphoma patients: a single-center retrospective study.
Annals of hematologyFive-Year Follow-Up of Patients With Relapsed and Refractory Classic Hodgkin Lymphoma Treated With Low-Dose Nivolumab (40 mg): A Matched Cohort Study With Standard-Dose Therapy.
Hematological oncologyAssociation between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma.
European journal of nuclear medicine and molecular imagingLong-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
British journal of haematologyLong-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience.
Haematologica[Treatment strategy for classical Hodgkin lymphoma and future perspectives].
[Rinsho ketsueki] The Japanese journal of clinical hematologyImmune Checkpoint Molecule Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Expressed in Lymphoma Subtypes With and Without Epstein-Barr Virus.
Applied immunohistochemistry & molecular morphology : AIMMPredictors of first line treatment failure in classic Hodgkin lymphoma: A comprehensive review.
Critical reviews in oncology/hematologyCardiovascular and Oncologic Considerations in Adult Hodgkin Lymphoma: JACC: CardioOncology State-of the-Art Review.
JACC. CardioOncologyHodgkin Lymphoma Classification-From Historical Concepts to Current Refinements.
CancersConcomitant Diagnosis and Therapeutic Response of Large-vessel Vasculitis and Hodgkin Lymphoma on 18 F-FDG PET/CT.
Clinical nuclear medicine[Application of Fine-Needle Aspiration in the Diagnosis of Classic Hodgkin Lymphoma and Its Clinical Pathological Analysis].
Zhongguo shi yan xue ye xue za zhiTumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq.
Blood advancesDiagnostic challenges and considerations in CD30-negative classical Hodgkin lymphoma from biopsy specimens.
Annals of diagnostic pathologyClassic Hodgkin lymphoma: the journey over the destination.
BloodShifting the Balance of Therapeutic Radiation in Adolescent and Young Adult Hodgkin Lymphoma.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyFollicular Helper T-Cell Lymphomas With Epstein-Barr Virus-Positive Neoplastic Cells: A Rare Scenario With Diagnostic Implications.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncRisk of lymphoma among people with HIV in the United States, 2001-2019.
Journal of the National Cancer InstituteLymph node transcriptomic profiles suggest susceptibility to bleomycin-induced pulmonary toxicity in classic hodgkin lymphoma.
Scientific reportsAtrial fibrillation following bendamustine in three lymphoma patients.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersNon-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies.
Blood advancesCamidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.
Blood advancesHodgkin Lymphoma: An Unusual Presentation With Hemophagocytic Lymphohistiocytosis.
CureusTranscriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.
bioRxiv : the preprint server for biologyThe evolution of treatment for pediatric advanced stage classic Hodgkin lymphoma - a narrative literature review.
Leukemia & lymphomaClassic Hodgkin lymphoma in a patient treated with ixekizumab for generalized pustular psoriasis.
European journal of dermatology : EJDImmune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies.
CancersTumor-associated macrophages: potential role in skeletal involvement in classic Hodgkin lymphoma.
The journal of pathology. Clinical researchObservations on seasonal occurrence in lymphomas with proven or presumed infectious etiology.
Frontiers in oncologyLow-dose PD-1 inhibition in relapsed/refractory classic Hodgkin lymphoma: systematic review and meta-analysis.
Investigational new drugsPositron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyLong non-coding RNA <I>LINC00926</i> is a biomarker for naïve B-cells with prognostic value in advanced stage classic Hodgkin lymphoma.
HaematologicaFertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.
The Lancet. OncologyAnaplastic large cell lymphoma: unusual clinical and pathologic findings: A report of the 2023 SH-EA4HP Lymphoma Workshop.
American journal of clinical pathologyEffusion cytology of EBV-associated lymphoma: a concise review.
Blood researchLymphoproliferative Disorders Mimicked by Tuberculosis: A Retrospective Study on Lateral Flow Urine Lipoarabinomannan (LF-ULAM) Limitations.
CureusComparison of Contemporary Radiation Therapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331.
International journal of radiation oncology, biology, physicsIncorporating novel therapies into the treatment of older patients with classic Hodgkin lymphoma.
Expert review of hematologyMediastinal grey-zone lymphoma: diagnostic and therapeutic challenges.
BMJ case reportsSerum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma.
Blood advancesPrimary Bone Marrow Classic Hodgkin Lymphoma With Haemophagocytic Lymphohistiocytosis.
EJHaemNivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.
Journal of clinical oncology : official journal of the American Society of Clinical OncologyTreatment of older patients with Hodgkin lymphoma.
Blood researchBurden of Chronic Health Conditions Among People With HIV and Common Non-AIDS-Defining Cancers.
Journal of the National Comprehensive Cancer Network : JNCCNClassic Hodgkin lymphoma in the cerebellum: a rare site for a common disease.
BloodCharacterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classic Hodgkin lymphoma.
HemaSphereTransplant-Free Salvage of Relapsed/Refractory Classic Hodgkin Lymphoma in Children, Adolescents, and Young Adults: An Emerging Role for Radiation Therapy.
International journal of radiation oncology, biology, physicsTumor-microenvironment and molecular biology of classic Hodgkin lymphoma in children, adolescents, and young adults.
Frontiers in oncologyImproved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study.
Cancer immunology, immunotherapy : CIIImmune Deficiency/Dysregulation-Associated EBV-Positive Classic Hodgkin Lymphoma.
CancersA comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.
BloodOptimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD-1 blockade.
HemaSphereSynchronous clear cell renal cell carcinoma and classic Hodgkin lymphoma.
IJU case reportsBCL11B helps to define T-lineage in lymphomas/leukaemias with a mixed/ambiguous immunophenotype.
PathologyNivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed/refractory Hodgkin lymphoma.
HemaSphereEBV-positive Hodgkin lymphoma with immunosuppressive microenvironment during IL-23 inhibitor therapy for psoriasis.
medRxiv : the preprint server for health sciencesPrimary Gastrointestinal EBV-Associated Classical Hodgkin Lymphoma in Crohn Disease on Anti-TNF-α Therapy: A Rare Association.
JGH open : an open access journal of gastroenterology and hepatologyTailored Therapeutic Approach in a Patient With Diffuse Large B-Cell Lymphoma With Meningeal Infiltration, Concurrent Classic Hodgkin Lymphoma, and Smoldering Multiple Myeloma: A Case Report.
Cancer reports (Hoboken, N.J.)Allogenic stem cell transplantation response for relapsed or refractory Hodgkin lymphoma patients: An experience in Iran.
Transplant immunologyMolecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics.
Annals of hematologyDissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma.
BloodBendamustine supercharge plus brentuximab vedotin as early salvage therapy following failure to obtain complete metabolic remission after two cycles of adriamycin-bleomycin-vinblastine-dacarbazine for classic Hodgkin lymphoma in patients aged ≤ 60 years: Long-term efficacy results of a retrospective multicentre study.
British journal of haematologyPrognostic Impact of Quantitative Changes Between Baseline and Interim 18 F-FDG PET/CT in Pediatric Classic Hodgkin Lymphoma.
Clinical nuclear medicineIncorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination.
Journal of the National Cancer InstituteOutcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers.
Blood cancer journalProgression-free survival: a true endpoint in first-line treatment for classic Hodgkin Lymphoma?
Annals of oncology : official journal of the European Society for Medical OncologyDoes CD47 expression have prognostic significance in classical Hodgkin lymphoma?
Turkish journal of medical sciencesClassic Hodgkin Lymphoma With Primary Presentation as Lytic Bone Lesions and Pancytopenia: Report of a Pediatric Case and Review of Literature.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology SocietyFlow Cytometry for B-Cell Non-Hodgkin and Hodgkin Lymphomas.
CancersThe Impact of Radiotherapy and Attenuated Chemotherapy Regimens in Older Patients with Classic Hodgkin Lymphoma: A Real-Life Study from the ReLLi Network.
CancersThe mutational landscape and its longitudinal dynamics in relapsed and refractory classic Hodgkin lymphoma.
Annals of hematologyPD-L1/PD-L2 genetic profile in the molecular cytogenetic classification of classic Hodgkin lymphoma.
Virchows Archiv : an international journal of pathologyAutopsy Revealed an Extremely Rare Case of Hodgkin Lymphoma With Intranodal Extramedullary Hematopoiesis and Hemophagocytosis in a Patient With Severe Thrombocytopenia.
CureusA Post-transplant Immunosuppression Complication: Epstein-Barr Virus-Positive Classic Hodgkin Lymphoma Post-transplant Lymphoproliferative Disorder.
ACG case reports journalUtility of fine-needle aspiration cytology combined with flow cytometry in extramedullary hematolymphoid lesions - A cross-sectional study.
CytoJournalClassic Hodgkin lymphoma: Pathobiological features that impact emerging therapies.
Blood reviewsReal-World Data on Lymphoma in Adolescents and Young Adults (AYA)-Report From the Lymphoma and Related Diseases Registry (LaRDR).
EJHaemHead and Neck Classic Hodgkin, T and NK Lymphomas with Eosinophilia.
Head and neck pathologyHSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma.
BloodComputational pathology identifies a low B-cell content in the tumour microenvironment as a predictor of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.
Journal of clinical pathologyTopological importance of CD8+ T-cell enrichment in the tumor microenvironment of classic Hodgkin lymphoma.
Annals of hematologyTargeted immunotherapy in the treatment of childhood and adolescent classic Hodgkin lymphoma.
Clinical advances in hematology & oncology : H&OInflammatory pseudotumor-like extranodal classic Hodgkin lymphoma manifesting as bowel perforation in acquired immunodeficiency syndrome patient with disseminated leishmaniasis: a case report and approach to differential diagnosis.
Journal of gastrointestinal oncologySafety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis.
BMC cancerLong-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial.
Leukemia researchPeripheral T-Cell Lymphoma Following Treatment of Hodgkin Lymphoma: Report of One Case and Literature Review.
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae SinicaeFollicular Helper T-cell Lymphoma With Hodgkin/Reed-Sternberg-Like Cells Versus Classic Hodgkin Lymphoma: A Comparative Study.
The American journal of surgical pathologyTransplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults: A Nonrandomized Clinical Trial.
JAMA oncologyTransplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial.
JAMA oncologyCancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma.
Nature communicationsCase of Refractory Classic Hodgkin Lymphoma With a Germline Pathogenic Monoallelic Variant in the TNFRSF13B Gene.
Pediatric blood & cancerRecent progress in pathological understanding of adult T-cell leukemia/lymphoma in the new classification era.
Leukemia researchPathobiological Features and Therapeutic Opportunities Linked to TNF Family Member Expression in Classic Hodgkin Lymphoma.
CancersRising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin Lymphoma.
Seminars in radiation oncologyRare case of classic Hodgkin lymphoma in a patient with ulcerative colitis.
BMJ case reportsPrimary mediastinal large B-cell lymphoma from the clinic to genomics: Insights for pathologists.
Human pathologyWhen should we use it? The role of brentuximab vedotin in 2024.
Hematology. American Society of Hematology. Education ProgramHas PD-1 blockade changed the standard of care for cHL?
Hematology. American Society of Hematology. Education ProgramProteomic profiling identifies classic Hodgkin lymphoma patients at risk of bleomycin pulmonary toxicity.
Leukemia & lymphomaEpstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: Diagnostic overlaps and defining features.
Human pathologyPrognosis of patients with Hodgkin lymphoma and indeterminate response to PD-1 inhibitor therapy: considerations for application of LYRIC criteria in real clinical practice.
Annals of hematologyLiposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi-Center Real-Life Study.
Hematological oncologyAuthor Correction: Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma.
Scientific reportsLong-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases.
British journal of haematologyClassic Hodgkin Lymphoma: The LYSA pragmatic guidelines.
European journal of cancer (Oxford, England : 1990)Primary Refractory Discordant Diffuse Large B-Cell and Classical Hodgkin Lymphoma.
Journal of hematologyClinical use of circulating tumor DNA analysis in patients with lymphoma.
Human pathologyClassic Hodgkin lymphoma: An illustrative review of select diagnostic limitations and immunomorphological challenges.
Human pathologyParaneoplastic Proliferative Myositis on 18 F-FDG PET/CT.
Clinical nuclear medicine[Clinical study of immune-targeting combined with attenuated chemotherapy in the treatment of children with classic Hodgkin lymphoma].
Zhonghua er ke za zhi = Chinese journal of pediatricsFlow Cytometry for Non-Hodgkin and Hodgkin Lymphomas.
Methods in molecular biology (Clifton, N.J.)Proteomic Profiling of Lymph Nodes Differentiates Classic Hodgkin Lymphoma With and Without Skeletal Involvement.
European journal of haematologyPrognostic Evaluation of Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score and Hematological Indices in Classic Hodgkin Lymphoma.
International journal of laboratory hematologySudden cardiac death caused by Kawasaki coronary artery vasculitis in a child with Hodgkin's lymphoma. Case report and literature review.
Cardiovascular pathology : the official journal of the Society for Cardiovascular PathologyProviding Survivorship Care for a Young Adult With a History of Blood Cancer.
The Journal of adolescent health : official publication of the Society for Adolescent MedicineProtocol-Stipulated Dose Modification to Manage Chemotherapy-Induced Peripheral Neuropathy in Children, Adolescents, and Young Adults With High-Risk Hodgkin Lymphoma.
JCO oncology practiceEBV-Positive Classic Hodgkin Lymphoma and Primary Nodal T-Cell/NK-Cell Lymphoma Arising in the Background of Follicular Lymphoma.
Case reports in hematologyUtility of CCR7 to differentiate classic Hodgkin lymphoma and other B-cell lymphomas by flow cytometry and immunohistochemistry.
American journal of clinical pathologyIntegrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma.
JCO oncology practiceImplicit Flow Cytometric Diagnosis of Classic Hodgkin Lymphoma Using CD3+CD4+CD26- T-Cells.
Journal of clinical laboratory analysisNodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment.
HaematologicaSingle-cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes.
HemaSphereIncidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis.
Clinical lymphoma, myeloma & leukemiaAdvanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse.
Leukemia & lymphomaImmune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?
Pharmaceuticals (Basel, Switzerland)The Abundance of FOXP3, FOXP3/CD4 and CD8 Cells in the Microenvironment of Nodular Sclerosis and Mixed Cellularity Subtypes Is Associated with the Epstein-Barr Virus Status of Classic Hodgkin Lymphoma.
BiomedicinesPrimary Hodgkin Lymphoma of the Breast: A Case Report and Literature Review Examining the Use of Different Chemotherapy Regimens.
CureusCharacterization of the genomic landscape of HIV-associated lymphoma reveals heterogeneity across histological subtypes.
AIDS (London, England)PET/CT Response Assessment in Pediatric Hodgkin Lymphoma: Does Deauville Score 3 Reflect Negativity?
Journal of pediatric hematology/oncologyTransition From Epstein-Barr Virus (EBV)-Positive Rectal Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma in the Lung.
CureusAI-Based Computational H&E Staining Enables Spatial Transcriptomic Analysis in Classic Hodgkin Lymphoma.
International journal of surgical pathologyHIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma.
Blood advancesEpigenetic agents plus anti-PD-1 reprogram the tumor microenvironment and restore antitumor efficacy in Hodgkin lymphoma.
BloodEvaluation of the effects of MCVAC conditioning regimen followed by autologous hematopoietic stem cell transplantation in patients with relapsed and refractory Hodgkin lymphoma: A single-institution retrospective study.
Journal of clinical and experimental hematopathology : JCEHMechanisms of lymphoma-stromal interactions focusing on tumor-associated macrophages, fibroblastic reticular cells, and follicular dendritic cells.
Journal of clinical and experimental hematopathology : JCEHHistopathologic Features and Differential Diagnosis in Challenging Cases of Nodular Lymphocyte Predominant B-cell Lymphoma/Nodular Lymphocyte Predominant Hodgkin Lymphoma.
Journal of clinical and translational pathologyComposite Burkitt Lymphoma and Classical Hodgkin Lymphoma in an Human Immunodeficiency Virus (HIV)-Positive Patient.
Cureus[Analysis of 10 cases of brentuximab vedotin combined with chemotherapy in the treatment of children with refractory and or relapsed classic Hodgkin lymphoma].
Zhonghua er ke za zhi = Chinese journal of pediatricsInterim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305).
Cancer sciencePediatric discordant lymphoma with classic Hodgkin lymphoma in cervical lymph nodes and high-grade B-cell non-Hodgkin lymphoma in bone marrow: a case report from Pakistan.
EcancermedicalscienceCirculating tumor DNA assisting lymphoma genetic feature profiling and identification.
Annals of hematologyThe role of response adapted therapy in the era of novel agents.
Seminars in hematologyA proteome-wide analysis unveils a core Epstein-Barr virus antibody signature of classic Hodgkin lymphoma across ethnically diverse populations.
International journal of cancerMolecular biomarkers in classic Hodgkin lymphoma.
Seminars in hematologyMultiplexed Spatial Profiling of Hodgkin Reed-Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer ResearchTowards IVDR-compliance by implementing quality control steps in a quantitative extracellular vesicle-miRNA liquid biopsy assay for response monitoring in patients with classic Hodgkin lymphoma.
Journal of extracellular biologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Doença de Hodgkin.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Doença de Hodgkin
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Classic hodgkin lymphoma associated with Epstein-Barr virus reactivation during vedolizumab therapy for ulcerative colitis.
- A Randomized Phase 2 Study of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed Hodgkin Lymphoma.
- Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.Journal of clinical oncology : official journal of the American Society of Clinical Oncology· 2026· PMID 41512237mais citado
- Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq.
- Clinicopathologic patterns and treatment outcomes of pediatric classic hodgkin lymphoma in Ethiopian newly opened cancer treatment centers.
- Gene expression profile of adult T-cell leukemia/lymphoma with human T-cell lymphotropic virus type 1-infected Hodgkin and Reed-Sternberg-like cells is more similar to classic Hodgkin lymphoma than typical adult T-cell leukemia/lymphoma.
- Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial.
- SSTR2 expression in EBV-positive and EBV-negative lymphomas.
- Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial.
- Successful Treatment of Isolated Bone Marrow Classic Hodgkin Lymphoma in a Patient With Cartilage Hair Hypoplasia.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:391(Orphanet)
- OMIM OMIM:236000(OMIM)
- MONDO:0009348(MONDO)
- GARD:16529(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Artigo Wikipedia(Wikipedia)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
